Fluoxetine Hydrochloride

前言 脓毒症相关性脑病（SAE）是指由脓毒症引发、排除中枢神经系统直接感染后出现的弥漫性脑功能障碍，是重症医学领域极为常见的脓毒症并发症，在重症监护室脓毒症患者中的发生率可高达 70%。 该病临床表现跨度极大，轻者表现为谵妄，重者可进展至昏迷，同时可伴随脑电图异常、癫痫发作等神经电生理改变。 临床已明确，SAE 的严重程度与患者死亡率呈正相关，且存活患者常遗留长期认知功能障碍、躯体功能残疾及神经精神异常，严重影响远期生活质量。 SAE 的病理生理机制极为复杂，涉及神经传递紊乱、脑细胞功能异常、血脑屏障损伤、神经血管耦合障碍等多重通路，核心病理过程为神经炎症与脑缺血，细胞层面则表现为能量代谢衰竭与氧化应激损伤，其中额叶皮质、海马体、边缘系统及脑干等脑区对上述损伤尤为敏感。 当前临床针对 SAE 尚无特异性治疗手段，管理核心以控制原发病脓毒症、落实谵妄防治策略、规避神经毒性药物为主。 本文系统梳理 SAE 的流行病学、发病机制、临床特征、诊断评估、远期预后及临床管理策略，剖析当前研究瓶颈与未来方向，为重症医护人员的临床实践与科研思路提供全面参考。一、脓毒症相关性脑病的核心发病机制 SAE 的病理生理网络呈多通路、交叉性特点，目前尚未完全阐明，现有研究证实其由外周炎症信号传导、脑内免疫激活、血管屏障破坏、代谢失衡等多重机制共同介导，各通路相互作用形成恶性循环，最终引发脑功能障碍。 脓毒症相关脑病的神经生物学。图A：脓毒症期间介导脑-外周信号传导的神经和体液通路。迷走神经和背根神经节神经元可感知外周炎症，它们分别投射到孤束核（NTS）和丘脑（TH）。同时，细胞因子等循环炎症介质可通过室周器官（包括最后区（AP)）进入大脑并激活局部神经元。大脑激活会募集传出自主神经通路，通过脊髓刺激交感神经输出，通过迷走神经背运动核（DMN）刺激副交感神经输出，以调节外周免疫反应，这一过程被称为抗炎反射。与此同时，下丘脑（HYP）和下丘脑-垂体-肾上腺（HPA）轴的激活会导致免疫调节激素释放入血，进一步抑制外周炎症。由BioRender.com制作。图B：脓毒症相关脑病的主要病理生理机制，从全身因素到细胞功能障碍。简言之，全身炎症反应以及其他全身因素（如药物神经毒性……）会激活多种脑内过程（如神经炎症、血管病变……）和细胞内功能障碍（如生物能量衰竭……），这些过程会累及特定脑区，进而导致急性神经系统表现和长期心理认知功能受损。图C：脑损伤的生物标志物。ICAM-1：细胞间黏附分子1；GFAP：胶质纤维酸性蛋白；NfH：神经丝重链；NfL：神经丝轻链；NSE：神经元特异性烯醇化酶；NT-proCNP：C型利钠肽氨基末端前肽；UCHL-1：泛素C末端水解酶L1。（一）脑信号传导与神经 - 免疫双向调控 脓毒症状态下，外周炎症信号通过体液通路与神经通路两条途径传入中枢。 体液通路中，循环细胞因子、病原体相关分子模式及损伤相关分子模式，通过载体转运、血脑屏障破损渗漏或室周器官直接接触等方式进入脑内；神经通路则通过迷走神经、背根神经节感知外周炎症，将信号传导至孤束核与丘脑，激活脑内神经调控环路。 上述信号激活后，一方面启动生理性抗炎反射，通过交感、副交感神经调控外周免疫；另一方面则引发病理性脑功能紊乱，同时下丘脑 - 垂体 - 肾上腺轴异常激活，进一步加重免疫失衡。 重症状态下，这种神经 - 免疫双向调控失衡，既表现为全身过度炎症与免疫抑制并存，也直接导致中枢神经功能异常，成为 SAE 发生的始动因素。（二）血脑屏障结构与功能破坏 血脑屏障是维持脑内稳态的核心结构，脓毒症引发的全身炎症是导致血脑屏障损伤的关键诱因。 炎症介质直接激活脑内血管内皮细胞，诱导紧密连接蛋白降解、血管内皮糖萼脱落，同时上调基质金属蛋白酶表达，进一步加重屏障通透性增加。 血脑屏障破坏后，外周渗透活性物质引发脑水肿，促炎因子进入脑内启动神经炎症级联反应，同时脑内物质转运功能紊乱，导致神经毒性物质蓄积、必需营养物质输送不足，直接损伤神经元功能，成为 SAE 病理进程的核心环节。（三）中枢神经炎症激活 神经炎症是 SAE 的核心病理特征，以小胶质细胞过度激活为核心表现，同时累及脑内皮细胞、星形胶质细胞及外周浸润免疫细胞。 脓毒症早期，脑内血管内皮细胞率先发生转录水平改变，随后小胶质细胞出现肥大、激活，释放大量 IL-1β、TNF-α、IL-6 等促炎因子，激活 NLRP3 炎症小体，诱导一氧化氮、前列腺素等炎症介质释放。 激活的小胶质细胞还会通过补体 C1q 介导突触吞噬，直接破坏突触结构，既引发急性谵妄、意识障碍，也介导长期认知损伤。此外，内源性损伤相关分子模式会进一步放大神经炎症，形成炎症级联反应，加重脑内微环境紊乱。（四）脑能量代谢衰竭与氧化应激损伤 大脑是全身能量消耗最高的器官，需持续 ATP 供应维持神经功能，脓毒症状态下线粒体功能障碍是能量代谢异常的核心原因。 脓毒症引发的氧化应激导致线粒体结构损伤、活性氧过量蓄积，超出机体抗氧化代偿能力，既直接破坏细胞结构，又导致 ATP 生成不足，引发脑内能量代谢崩溃。 受损线粒体释放后还会作为损伤相关分子模式，进一步加重神经炎症，形成代谢紊乱与炎症反应的恶性循环，最终导致神经元、胶质细胞功能不可逆损伤。（五）脑微循环功能异常 大脑无内在能量储备，完全依赖脑血流量维持灌注，脓毒症状态下脑微循环紊乱具有显著的隐匿性。 宏观层面脑血流量可表现为升高、降低或无明显变化，但局部微循环已出现明显异常，表现为脑血流自身调节功能受损、脑血管对二氧化碳反应性下降、微血栓形成、红细胞流变学异常。 临床中常出现全身血流动力学稳定，但脑局部灌注不足的现象，经颅多普勒监测发现，约三分之一脓毒症患者存在脑灌注压降低，而颅内高压罕见。 这种宏观与微观灌注的分离现象，是 SAE 发生的重要血管机制，也对临床脑灌注监测提出了更高要求。（六）神经递质系统紊乱 神经传递异常是 SAE 出现意识、认知、情绪障碍的直接原因，脓毒症相关炎症可广泛扰乱胆碱能、谷氨酸能、GABA 能、5 - 羟色胺能等多重神经递质系统。 海马体胆碱能、5 - 羟色胺能紊乱直接引发记忆损伤，杏仁核神经传递异常则导致焦虑等情绪障碍，TNF-α 等炎症因子直接调控突触谷氨酸释放，诱发兴奋性毒性。 临床研究证实，脓毒症患者脑脊液突触蛋白、血浆胆碱酯酶及神经递质前体浓度均出现异常，但目前针对神经递质的靶向干预临床试验尚未获得阳性结果，提示递质紊乱的复杂性与个体化差异。二、受累脑结构与功能网络 SAE 的脑损伤具有区域选择性，特定脑区与神经网络对炎症、缺血、代谢损伤更为敏感，其损伤模式直接对应临床症状与远期预后。（一）脑干功能障碍 脑干是调控觉醒、睡眠 - 觉醒周期、心肺自主神经功能及免疫调节的核心结构，也是 SAE 的关键受累部位。脓毒症相关神经炎症与缺血可引发脑干神经元凋亡、组织形态改变，尤以延髓、下网状结构受累显著。 临床中，深镇静脓毒症患者咳嗽反射消失、体感诱发电位 P14 潜伏期延长、眼脑反射消失，均提示脑干功能损伤，且与患者死亡率、镇静停药后苏醒延迟密切相关。脑干自主神经中枢受损还会引发血流动力学不稳定、免疫调节紊乱，进一步加重脓毒症病情。（二）额叶 - 海马 - 杏仁核环路损伤 海马体、额叶皮质与边缘系统是 SAE 急性与慢性损伤的核心靶区，病理研究证实该区域小胶质细胞激活、血脑屏障破坏、葡萄糖代谢异常更为显著。炎症因子与氧化应激直接破坏海马体长时程增强效应，导致学习记忆功能受损，远期海马萎缩与言语记忆、执行功能障碍直接相关。 杏仁核早期激活则与重症后创伤后应激障碍、焦虑情绪相关，近红外光谱监测显示的前额叶连接异常，可作为 SAE 患者预后评估的重要指标。（三）意识相关神经网络破坏 意识障碍是 SAE 的核心临床表现，源于额顶网络、丘脑 - 纹状体环路、脑干觉醒网络的功能连接受损。炎症与代谢损伤导致全脑网络连接性下降，默认模式网络功能异常，磁共振可见大脑皮质、丘脑广泛血管源性与细胞毒性水肿。 脑电图表现为背景弥漫性慢波、低电压、爆发抑制及波形无反应性，高密度脑电图可更精准评估网络损伤程度，为短期预后判断提供依据。三、临床特征与鉴别诊断（一）核心临床特征 SAE 的临床表现需与疾病行为严格区分：疾病行为是全身炎症引发的适应性生理反应，表现为疲劳、快感缺失、情绪低落、社交退缩，认知功能与意识水平保留，随炎症控制可自行缓解；而 SAE 是病理性脑功能障碍，以意识、认知、注意力异常为核心，属于器质性损伤。 SAE 的症状谱从轻度谵妄至深度昏迷，机械通气患者躁动、激越等行为异常发生率仅 5%-10%，多与镇静药物使用相关；部分患者可出现自主神经症状，如心率血压波动、多汗、瞳孔散大、震颤；运动症状少见，偶见齿轮样强直、肌阵挛，全面性癫痫发作发生率低于 5%。 需重点强调，局灶性神经功能缺损、颈项强直、头痛等表现并非 SAE 的典型症状，出现此类表现需立即排除中枢神经系统感染、脑出血、脑梗死等其他病因。（二）电生理评估特征 脑电图是 SAE 诊断与病情分层的核心工具，评估维度包括背景活动、癫痫样放电、波形反应性。脑病严重程度与脑电优势频率（α、θ、δ 波）、波幅、连续性直接相关：θ 波、δ 波慢波活动发生率分别为 10%-50%、30%-60%，低电压、不连续背景发生率 10%-60%，爆发抑制发生率 0-8%，三相波发生率约 20%，电发作发生率可达 30% 且多为非惊厥性，需持续脑电图监测识别。 脑电图无反应性、不连续背景、周期性放电均为患者死亡的独立危险因素，同时可提前预测谵妄发生，是临床神经监测的重要手段。（三）神经影像学特征 磁共振成像是评估 SAE 脑结构损伤的最优手段，可见分水岭区缺血、白质病变、后脑可逆性脑病综合征、脑水肿及脑萎缩，其中大脑皮质、白质、海马体、杏仁核萎缩最为显著，深部灰质与小脑相对保留。 影像学异常数量、缺血性病灶存在与患者不良预后直接相关。但因重症患者转运风险高，磁共振检查仅适用于血流动力学稳定、头颅 CT 无明显异常且代谢紊乱纠正后仍意识障碍的患者，用于排除隐匿性脑损伤。四、生物标志物的临床应用与探索 SAE 生物标志物主要分为外周血标志物、脑脊液标志物与影像电生理标志物，临床以血标志物为主要筛查手段，可反映神经元、胶质细胞、神经血管、轴索损伤及小胶质细胞激活状态。 神经元胞体损伤标志物以神经元特异性烯醇化酶、泛素羧基末端水解酶 L1 为代表；胶质细胞损伤标志物为 S100B、胶质纤维酸性蛋白；神经血管屏障损伤标志物包括 E - 选择素、细胞间黏附分子 1、C 型利钠肽前体；轴索损伤标志物以神经丝轻链蛋白最具潜力，特异性与可靠性最优；脑脊液可溶性髓系细胞触发受体 2 可反映小胶质细胞激活，但外周血浓度过低、临床应用受限。 临床常用 S100B 与神经元特异性烯醇化酶，前者灵敏度高，后者特异度优，均可用于预后评估。但标志物解读需排除年龄、容量状态、肾功能、基础神经系统疾病等混杂因素，推荐早期基线检测 + 动态随访监测。目前尚无统一的临床截断值，主要用于区分暂时性脑功能紊乱与结构性脑损伤。五、远期预后与长期并发症 SAE 已成为脓毒症患者远期致残的核心原因，约三分之一存活者出院后 3-12 个月出现认知障碍，累及记忆、执行功能、信息处理速度、注意力等多个领域，损伤可持续数年，严重程度堪比轻度认知障碍或早期痴呆。 此外，SAE 患者癫痫年发生率达 1.3%，为普通住院患者的 4 倍，年轻患者、慢性肾病患者风险更高；躯体功能方面，患者常遗留日常生活能力下降，长期依赖他人照护；神经精神并发症以焦虑、抑郁、创伤后应激障碍最为常见。 远期不良结局的危险因素包括高龄、基础合并症、重症病程长、长期制动、住院期间心理应激等，认知储备低下、谵妄持续时间是独立危险因素。六、临床管理策略（一）基础管理：SAE 防治的核心手段 当前 SAE 无特异性治疗药物，临床管理以三大核心原则为主：原发病控制 严格遵循脓毒症诊疗指南，快速控制感染、纠正血流动力学紊乱，从源头阻断炎症信号向中枢传导；并发症管控 动态监测并纠正电解质紊乱、肝肾功能异常，规避具有神经毒性的抗菌药物，维持合理氧合、血糖水平与脑灌注，避免过度氧疗、盲目提升平均动脉压等有害干预；谵妄集束化管理 全面落实 ABCDEF 集束化策略，包括疼痛规范化评估、自主觉醒与呼吸试验、个体化镇静镇痛选择、谵妄持续监测、早期活动与康复、医患及家属赋能，集束化策略执行程度与患者临床结局呈剂量依赖性改善。 镇静药物方面，右美托咪定可减轻全身炎症反应，但未降低谵妄发生率，且存在血流动力学不耐受风险；氟哌啶醇无法预防谵妄、缩短谵妄持续时间，但可用于控制激越、精神症状，可能对生存有潜在获益。（二）特异性治疗：基础与临床研究探索 针对 SAE 病理机制的靶向治疗仍处于研究阶段，核心靶点包括神经炎症、血脑屏障、神经递质、线粒体功能等：抗神经炎症治疗 米诺环素可抑制小胶质细胞激活、减轻炎症因子释放、保护血脑屏障；CD137L 阻断剂、TNF-α 拮抗剂可减轻脑内炎症；IL-6 受体拮抗剂可减少重症患者谵妄与昏迷时间；迷走神经刺激具有潜在抗炎价值，但他汀类、卡巴拉汀临床效果未证实；血脑屏障保护 间充质干细胞、氢气疗法、蛋白激酶 C-δ 抑制剂可减轻屏障损伤，鼻内胰岛素在动物实验中可改善脑内炎症与认知功能；神经递质调节 美金刚可降低脑内谷氨酸浓度、减轻神经炎症；氟西汀、左旋多巴可改善动物模型认知与记忆损伤；其他靶点 线粒体生物合成激活剂、抗氧化剂、基于脑血流自身调节的血压调控策略均在探索中，左乙拉西坦用于脓毒症休克患者抗癫痫、降低创伤后应激障碍的临床试验正在开展。 癫痫发作的治疗需遵循指南，结合肝肾功能选择药物，规避不良反应。 SAE的管理。该算法优先采用务实的方法，神经影像学和神经生理学检查并非系统性进行，而是以临床观察为指导。该算法强调对症治疗和控制促妄想因素的重要性。对于重度急性脑病，尚无特异性治疗方法。七、研究展望与临床挑战 当前 SAE 研究仍存在多重瓶颈：尚无特异性临床、电生理或生物学诊断指标，难以与其他代谢性脑病精准区分；病理生理机制的交叉性导致单一靶点干预效果不佳；缺乏 validated 生物标志物指导诊疗与预后分层；临床研究因 SAE 与谵妄重叠、入组标准不统一而难以推进。 未来研究核心方向包括：挖掘 SAE 特异性生物标志物与脑电图特征；明确关键病理靶点，开展精准靶向治疗；解析脑修复与可塑性机制，减少远期认知损伤；建立 SAE 专属诊疗流程与远期随访体系。在特异性治疗问世前，临床仍以脓毒症控制 + 谵妄对症管理为核心，其防治效果本质上依赖于脓毒症的规范化救治。八、临床核心问题解析 疾病行为与低活动型谵妄的鉴别疾病行为是炎症介导的适应性反应，起病隐匿、意识与认知保留、随炎症缓解自行恢复；低活动型谵妄是 SAE 的常见表现，起病突然、注意力与认知受损、伴脑电图异常，预后更差，需通过 CAM-ICU 等标准化工具联合神经评估鉴别。 SAE 与普通谵妄的诊疗差异谵妄为多因素导致的临床综合征，SAE 则是脓毒症特异性炎症、血脑屏障损伤介导的器质性脑病，预后更差、远期认知风险更高；管理上除常规谵妄防治外，需更注重抗炎、脑灌注优化与神经保护，而非单纯镇静调整。 SAE 关联不良预后的核心原因SAE 既是脓毒症严重程度的标志物，也会通过脑干自主神经紊乱、意识障碍引发误吸、制动、继发感染，同时放大全身炎症与免疫抑制，形成脑 - 体恶性循环，远期则因脑结构损伤导致认知与功能残疾。 SAE 缺乏特异性治疗的原因病理机制多通路交叉、无特异性诊断标志物、临床诊断以排他性为主、与普通谵妄表型重叠，导致靶向药物研发与临床试验开展难度极大。 SAE 患者的远期随访策略出院后需开展认知功能筛查、心理状态评估，制定个体化认知康复与躯体康复方案，为患者及家属提供健康宣教，将 SAE 随访纳入重症后综合征全程管理体系。结论 脓毒症相关性脑病是脓毒症常见且危害极大的并发症，具有高发生率、高死亡率、高远期致残率的特点，其病理生理机制涉及神经 - 免疫调控、血脑屏障、能量代谢、微循环等多重网络，损伤具有明确的脑区选择性。 当前临床诊断依赖临床评估、脑电图与生物标志物，治疗以原发病控制与对症支持为主，尚无特异性干预手段。 未来需通过基础研究解析核心病理靶点，通过临床研究挖掘特异性诊断标志物与精准治疗方案，同时建立覆盖急性期诊疗、慢性期康复的全程管理体系，以改善 SAE 患者的短期生存与远期生活质量。

Scientists have uncovered evidence that serotonin, the chemical best known for regulating mood, may also speed the progression of a common heart valve disease in some people. The research suggests that patients with degenerative mitral regurgitation who take SSRI antidepressants and carry a specific genetic variant may develop severe valve damage sooner, potentially requiring surgery at a younger age.Serotonin is usually associated with mood, sleep, and digestion. But research published in 2023 suggests this chemical messenger may also influence a small structure that performs a vital job during every heartbeat: the mitral valve. The multicenter investigation found evidence that reduced activity of the serotonin transporter may accelerate damaging changes in valves already affected by degenerative mitral regurgitation (DMR). Researchers at Columbia University's Department of Surgery led the work in collaboration with the Pediatric Heart Valve Center at Children's Hospital of Philadelphia (CHOP), the University of Pennsylvania, and the Valley Hospital Heart Institute. The study was supported by the National Heart, Lung, and Blood Institute and was co led by Columbia's Giovanni Ferrari, PhD, and CHOP's Robert J. Levy, MD. The findings were published in Science Translational Medicine in 2023. A Small Heart Valve With a Critical Role The mitral valve sits between the heart's left atrium and left ventricle. The left atrium receives oxygen rich blood returning from the lungs, while the left ventricle pumps that blood throughout the body. Each time the heart contracts, the mitral valve should close firmly. It functions like a one way gate, keeping blood from flowing backward into the upper chamber. DMR is one of the most common forms of heart valve disease. As the valve tissue degenerates, the thin flaps that should meet neatly can thicken, stretch, or lose their normal shape. The valve can no longer seal completely, allowing blood to leak backward into the left atrium (regurgitation). This leak can raise pressure toward the lungs while reducing the amount of oxygen rich blood that moves forward through the heart. Some people have no noticeable symptoms at first. As the condition progresses, however, fatigue and shortness of breath can develop. The heart must also work harder to maintain circulation. Over time, that added strain can permanently damage the heart and contribute to serious conditions such as atrial fibrillation and heart failure. Atrial fibrillation is an irregular heart rhythm, while heart failure means the heart cannot pump enough blood to meet the body's needs. Medicines can ease symptoms and help manage complications, but they cannot reverse the underlying degeneration of the mitral valve. "Certain medications can ease the symptoms and prevent complications, but they do not treat the mitral valve," says Ferrari, scientific director of the Cardiothoracic Research Program at Columbia. "If the degeneration of the mitral valve becomes severe, surgery to repair or replace the valve is needed." Current medical guidelines evaluate heart valve disease by considering symptoms, valve anatomy, the severity of the leak, imaging results, and how the heart and lung circulation are responding. Why Serotonin Matters Beyond Mood Serotonin is a chemical messenger with jobs throughout the body. It contributes to emotional state, digestion, sleep, memory, and blood clotting. In the brain, it acts as a neurotransmitter involved in regulating mood. Changes in serotonin signaling have long been associated with conditions such as anxiety and depression. That relationship is complex, however, and neither condition can be explained simply as a shortage of one chemical. Serotonin communicates by attaching to receptors on a cell's surface. This contact sends a signal that tells the cell how to respond. A protein called the serotonin transporter (SERT or 5-HTT) helps end that signal. It carries serotonin into the cell so the chemical can be reabsorbed and recycled. This process is known as serotonin reuptake. Selective serotonin reuptake inhibitors (SSRIs) reduce the transporter's ability to take serotonin back into cells, leaving more serotonin available for a longer time. This effect can help relieve symptoms of mood disorders. SSRIs are among the most widely prescribed antidepressants. They include fluoxetine (Prozac) and sertraline (Zoloft). Because SSRIs reduce SERT activity, the researchers wanted to know whether the same mechanism could unintentionally affect heart valve tissue, particularly in people whose valves were already degenerating. What Researchers Found in Patients and Mice The team reviewed clinical information from more than 9,000 patients who had undergone mitral valve repair or replacement for DMR. The researchers also evaluated 100 mitral valve biopsies, which are small tissue samples examined in a laboratory. "Studying the data of these patients, we found that taking SSRIs was associated with severe mitral regurgitation that needed to be treated with surgery at a younger age than for patients not taking SSRIs," says Ferrari. That finding showed an association, not cause and effect. The patient data could not prove that SSRIs caused the disease to progress more quickly. Observational studies cannot rule out other differences between groups that might influence when patients require surgery. The researchers therefore explored the possible biological mechanism in mice and human valve cells. They studied transgenic mice that lacked the SERT gene and found that the animals developed thicker mitral valves. Normal mice treated with high doses of SSRIs also developed thickened valves. These experiments supported the possibility that unusually low SERT activity can contribute to structural remodeling of the valve. A Genetic Clue to Greater Valve Vulnerability The researchers also examined 5-HTTLPR, a region of the SERT gene that helps control how active the serotonin transporter is. They identified genetic variants that changed SERT activity in mitral valve cells. A "long" variant was associated with lower activity, particularly in people who inherited two copies (one maternal and one paternal). Patients with DMR who carried the "long-long" variant underwent mitral valve surgery more often than patients with other variants. Laboratory experiments offered a possible explanation. Mitral valve cells from patients with the "long-long" variant reacted more strongly to serotonin and produced more collagen. Collagen normally gives tissue structure and strength, but excessive collagen can make a valve thicker and stiffer, changing its shape and movement. Cells with the "long-long" variant were also more sensitive to fluoxetine than cells carrying other variants. The findings suggest that an already damaged valve may be especially vulnerable when serotonin exposure, reduced transporter activity, and genetic susceptibility occur together. Could a Simple DNA Test Guide Care? For patients with DMR and the "long-long" variant, the researchers proposed that taking an SSRI could further reduce SERT activity in the mitral valve. They suggested testing people with DMR for 5-HTTLPR. The test could be performed using DNA collected from a blood sample or mouth swab. In theory, identifying patients with low SERT activity could help doctors determine who might need closer monitoring or earlier surgery. "Assessing patients with DMR for low SERT activity may help identify patients who may need mitral valve surgery earlier," says Ferrari. "Promptly fixing a mitral valve that is very leaky would protect the heart and could prevent congestive heart failure." This type of genetic testing has not become a standard part of heart valve care. Major guidelines continue to focus primarily on symptoms, valve structure, leak severity, heart function, and imaging findings. Clinical studies would be needed to establish whether adding genetic testing actually improves treatment decisions and patient outcomes. What the Findings Do Not Mean The researchers did not observe harmful effects from normal SSRI doses or the "long-long" variant in cells obtained from healthy human mitral valves. "A healthy mitral valve can probably stand low SERT activity without deforming," says Ferrari. "It is unlikely that low SERT can cause degeneration of the mitral valve by itself. SSRIs are generally safe for most patients. Once the mitral valve has started to degenerate, it may be more susceptible to serotonin and low SERT." That distinction is important. The findings do not suggest that SSRIs generally damage healthy heart valves. They also do not justify stopping or changing antidepressant treatment without guidance from a prescribing clinician. The strongest signal appeared in people whose mitral valves had already begun to degenerate. Even in that group, the human findings were observational and could not establish that antidepressants directly caused earlier disease progression. The original research raised two practical questions for future studies. One is whether patients with DMR who respond well to SSRIs should receive regular monitoring for signs that the valve is worsening. The other is whether patients who do not respond well to an SSRI might benefit from switching to another type of antidepressant rather than increasing the SSRI dose. Those approaches have not yet been validated in clinical trials. Later Studies Expand the Serotonin Connection Research published since 2023 has added support to serotonin's possible role in heart valve remodeling. Much of that evidence, however, still comes from animals, cells, or relatively small observational studies. A 2024 study found that mice with deficient SERT activity were more susceptible to fibrotic changes in their cardiac valves and left ventricular heart muscle. Fibrosis is the buildup of stiff, scar like tissue that can interfere with normal movement and function. That study pointed to HTR2B, one of the cell receptors activated by serotonin, as an important driver of the damaging response. Mitral valve cells appeared particularly responsive to serotonin. The results broadened the concern beyond isolated thickening of the mitral valve, although animal findings cannot determine what happens in people taking standard doses of antidepressants. Evidence From Another Major Heart Valve A study published in 2025 investigated serotonin in aortic stenosis, a different type of heart valve disease. The aortic valve controls blood leaving the heart, and aortic stenosis develops when this valve becomes thick, stiff, and narrow. The researchers compared 38 people with severe aortic stenosis with 38 control participants matched for factors including age, sex, and major medical conditions. Patients with severe aortic stenosis had higher serum levels of serotonin and its primary breakdown product. The study supported the idea that serotonin signaling may be involved in more than one type of valve disease. However, the research included only 76 people and measured them at a single point in time. It could not determine whether elevated serotonin contributed to the disease, resulted from it, or reflected another biological process. An Experimental Drug Target Emerges In February 2026, researchers reported additional evidence connecting low SERT activity with aortic valve disease. The study examined valve tissue from 66 patients undergoing replacement for severe aortic stenosis and compared it with normal donor valves. Diseased valves showed reduced SERT expression and stronger serotonin receptor signaling. Researchers then tested the pathway in mice. An experimental compound that blocked HTR2B helped preserve valve structure and improved measurements of blood flow during an early stage of fibrotic remodeling. Human cell experiments also suggested that low SERT activity can make valve cells more sensitive to damaging biological signals. These results make HTR2B an intriguing possible drug target, but the compound is not an approved treatment for heart valve disease. The mouse model represented early fibrotic changes rather than advanced, heavily calcified aortic stenosis. Additional animal studies and eventual human trials would be necessary before researchers could know whether blocking HTR2B is safe or effective in patients. A Broader Review Finds an Association A 2026 systematic review and meta analysis examined clinical studies involving medications that modify SERT activity. The pooled analysis reported a significant association between these drugs and heart valve disease, with an odds ratio of 2.76. An odds ratio compares the odds of an outcome between groups. It does not directly predict an individual patient's risk, and it does not prove that the medication caused the outcome. The review also covered a broader category of SERT modifying drugs, not only commonly prescribed SSRIs. Its authors acknowledged that mechanistic evidence remains limited. More detailed research is needed to separate the effects of different drugs, doses, treatment durations, underlying health conditions, and preexisting valve abnormalities. A Compelling Clue That Still Needs Clinical Proof Taken together, the findings published since 2023 make serotonin signaling a more plausible contributor to heart valve remodeling. They suggest that the original mitral valve findings may reflect a broader biological pathway rather than an isolated observation. The research also raises the possibility that doctors could eventually use genetic information to identify vulnerable patients or that scientists could develop treatments aimed at HTR2B. Such a strategy might block harmful fibrotic signaling without broadly interfering with serotonin's many essential functions elsewhere in the body. Important questions remain. Researchers need studies that follow patients over time, compare individual medications and doses, account for other health risks, and determine whether SERT testing changes care in a meaningful way. Human trials would also be required before any treatment targeting HTR2B could enter routine use. For now, regular cardiology care remains the practical priority for people with degenerative mitral regurgitation. The evidence offers a compelling explanation for why some damaged valves may deteriorate faster, but it does not replace imaging, clinical evaluation, or individualized decisions about antidepressant treatment.